Clearmind's AUD drug clears Phase 1/2a trial primary endpoint

Sam Goldstein

·Apr 14 2026, 11:52

Share to

Share to

Copy link

Key Takeaways:

CMND-100 met its primary endpoint in a Phase I/IIa trial for Alcohol Use Disorder.
The drug is a non-hallucinogenic, MEAI-based oral therapeutic for a major unmet need.
Positive data significantly de-risks the asset and opens pathways to Phase III trials.

Clearmind Medicine’s (Nasdaq: CMND) treatment for alcohol use disorder met its primary endpoint in a Phase I/IIa trial, the company announced Tuesday.

"These results are a major milestone for Clearmind and for the millions of patients seeking better solutions for Alcohol Use Disorder," Dr. Adi Zuloff-Shani, CEO of Clearmind, said in a statement.

The study evaluated CMND-100, a proprietary non-hallucinogenic, MEAI-based oral drug candidate. The positive outcome from the FDA-approved trial paves the way for more advanced, larger-scale Phase III testing required for commercial approval.

The positive clinical trial result significantly de-risks the company's lead asset. This could attract new institutional investment and positions the company as a potential acquisition target for larger pharmaceutical firms.

The successful trial validates the company's scientific platform and its neuroplastogen-derived therapeutic approach. Investors will now watch for the full data presentation and the company's timeline for initiating pivotal Phase III trials.

This article is for informational purposes only and does not constitute investment advice.